Acurx Pharmaceuticals Inc... (ACXP)

AI Score

Unlock

0.37

-0.02 (-3.92%)

At close: Apr 17, 2025, 3:59 PM

0.39

5.02%

After-hours: Apr 17, 2025, 04:54 PM EDT

Acurx Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020	Q2 2020	Q1 2020
Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross Profit	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Income	-11.32M	-16.44M	-16.73M	-3.46B	-3.46B	-3.46B	-3.46B	-17.62M	-17.38M	-11.46M	-12.56M	-14.01M	-12.81M	-11.28M	-7.95M	-4.8M	-4.6M	-3.51M	-2.19M	-1.28M
Interest Income	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pretax Income	-14.1M	-16.44M	-16.73M	-16.05M	-14.58M	-12.72M	-13.15M	-12.33M	-12.09M	-11.46M	-12.56M	-13.94M	-12.75M	-11.21M	-7.89M	-4.8M	-4.6M	-3.51M	-2.19M	-1.28M
Net Income	-2.83B	-2.84B	-16.73M	-16.05M	-14.58M	-7.43M	-7.86M	-7.03M	-6.8M	-11.46M	-12.56M	-13.94M	-12.75M	-11.21M	-7.89M	-4.8M	-4.6M	-3.51M	-2.19M	-1.28M
Selling & General & Admin	8.7M	9.91M	10.06M	9.47M	8.53M	7.19M	7.37M	7.37M	7.34M	7.42M	8.99M	11.25M	10.78M	9.51M	6.65M	3.19M	2.4M	1.76M	1.11M	594.37K
Research & Development	5.4M	6.52M	6.67M	6.58M	6.04M	5.53M	5.78M	4.95M	4.75M	4.04M	3.57M	2.76M	2.03M	1.77M	1.3M	1.61M	2.2M	1.75M	1.09M	684.73K
Other Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Expenses	14.1M	16.44M	16.73M	16.05M	14.58M	12.72M	13.15M	12.33M	12.09M	11.46M	12.56M	14.01M	12.81M	11.28M	7.95M	4.8M	4.6M	3.51M	2.19M	1.28M
Interest Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	5.2M	5.2M	5.2M	5.2M	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	-2.82B	-2.82B	-2.82B	-2.82B	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	14.1M	16.44M	16.73M	16.05M	14.58M	12.72M	13.15M	12.33M	12.09M	11.46M	12.56M	14.01M	12.81M	11.28M	7.95M	4.8M	4.6M	3.51M	2.19M	1.28M
Income Tax Expense	-4.38M	-4.38M	-4.39M	3.44B	3.44B	3.44B	3.44B	-5.3M	-7.97M	2.53M	-2.11M	-2.18M	-979.86K	-7.28M	-3.95M	-4.8M	-4.6M	-3.51M	-2.19M	-1.28M
Shares Outstanding (Basic)	16.26M	16.36M	15.82M	15.47M	13.46M	13.01M	12.19M	11.64M	11.61M	11.15M	10.26M	10.23M	6.97M	10.12M	6.97M	9.54M	9.54M	9.54M	9.54M	9.54M
Shares Outstanding (Diluted)	16.26M	16.36M	15.82M	15.47M	13.46M	13.01M	12.19M	11.64M	11.61M	11.15M	10.26M	10.23M	6.97M	10.12M	6.97M	9.54M	9.54M	9.54M	9.54M	9.54M
EPS (Basic)	-0.88	-1.09	-1.16	-1.18	-1.15	-0.59	-0.67	-0.65	-0.66	-1.22	-1.36	-1.67	-1.56	-1.29	-0.97	-0.5	-0.48	-0.37	-0.23	-0.13
EPS (Diluted)	-0.88	-1.09	-1.16	-1.18	-1.15	-0.59	-0.67	-0.65	-0.66	-1.22	-1.36	-1.67	-1.56	-1.29	-0.97	-0.5	-0.48	-0.37	-0.23	-0.13
EBITDA	-5.6M	-7.94M	-8.23M	-11.67M	-14.58M	-12.72M	-13.15M	-12.33M	-12.09M	-11.46M	-12.56M	-9.94M	-8.74M	-6.12M	-1.47M	-2.39M	-2.19M	-2.19M	-2.19M	-1.28M
EBIT	-14.1M	-16.44M	-16.73M	-16.05M	-14.58M	-12.72M	-13.15M	-12.33M	-12.09M	-11.46M	-12.56M	-14.01M	-12.81M	-11.28M	-7.95M	-4.8M	-4.6M	-3.51M	-2.19M	-1.28M
Depreciation & Amortization	4.38M	9.49M	12.61M	16.05M	14.58M	12.72M	13.15M	12.33M	12.09M	11.46M	12.56M	14.01M	12.81M	11.28M	7.95M	4.8M	4.6M	3.51M	2.19M	1.28M